Navigation Links
Blocking tumor-associated macrophages decreased glioblastoma's growth & extended survival in mice
Date:12/15/2013

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology (ASCB) annual meeting in New Orleans.

The rates of apoptosis, or programmed cell death, were higher in the mice treated with the experimental agent than in the untreated animals that also had high-grade glioblastomas, said Johanna Joyce, Ph.D., of the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City. As a result, the drug-treated laboratory mice survived many months longer than the untreated animals with the same cancer.

The experimental drug blocks cell receptors for colony-stimulating factor-1 (CSF-1R), which is essential to the differentiation and survival of tumor-associated macrophages and microglia (TAMS), which are the brain's front-line immune defense cells. The microenvironment that surrounds brain tumors contains many macrophages with this receptor.

Glioblastoma multiforme (GBM) is the most common and the most deadly adult primary brain tumor, with an average survival of just 14 months following diagnosis. Even with aggressive treatment by surgery, radiation and chemotherapy, most therapeutic approaches targeting the glioma cells in GBM fail.

Faced with this bleak picture, Dr. Joyce and colleagues MSKCC looked for an alternative strategy and turned to the cancer's cellular neighbors, the non-tumor cells that are part of the glioma microenvironment. In particular, they zeroed in on tumor-associated macrophages and TAMs.

When Dr. Joyce's lab used an inhibitor of the CSF-1 receptor (CSF-1R) to target TAMs in a mouse model of GBM, the treated mice survived many months longer than the control cohort. Their established, high-grade gliomas regressed in proliferation and malignancy, even though the glioma cells themselves were not the targets of the CSF-1R treatment.

With the TAMs blockaded by CSF-1 inhibitors, it was the tumor cells that showed increased rates of apoptosis. The TAMs were not even depleted in the treated mice, despite the drug blockade of their growth factor. Instead the TAMs survived by responding to growth factors secreted by the gliomas, including GM-CSF and IFN-γ, according to Dr. Joyce.

The MSKCC researchers also found that tumor spheres, freshly isolated from glioma patients in the surgery department at MSKCC, responded to the drug when implanted in animals. The CSF-1R blockade slowed intracranial growth in the patient-derived glioma xenografts.

Because GBM is the most common glioma, its genome was the first to be sequenced for the Cancer Genome Atlas, which parsed GBM into four genetic subtypes: proneural, neural, classical and mesenchymal. The mice used in Dr. Joyce's lab experiments model the proneural GBM subtype. All forms of GBM have a 2- to 3-person per 100,000 incidence rate in the U.S. and Europe, according to the National Brain Tumor Society. Because of its highly invasive phenotype, GBM is almost impossible to resect completely in surgery. Drug and radiation treatments are the standard follow-ups.

Dr. Joyce says that these new results, which were first reported only two months ago in Nature Medicine, http://www.ncbi.nlm.nih.gov/pubmed/24056773, are encouraging for planned clinical trials of CSF-1R inhibitors in combination with radiation therapy in glioma patients.

"We are optimistic that CSF-1R inhibitors may provide a more effective therapy than current treatments for the disease management of glioma patients," Dr. Joyce said.


'/>"/>

Contact: Cathy Yarbrough
cyarbrough@ascb.org
858-243-1814

John Fleischman
jfleischman@ascb.org

American Society for Cell Biology
Source:Eurekalert


Related biology news :

1. Pathogen study explores blocking effect of E. coli O157:H7 protein
2. Newly identified proteins make promising targets for blocking graft-vs.-host disease
3. Study suggests way to fight therapy resistant leukemia by blocking DNA repair
4. Blocking overactive receptor in Alzheimers recovers memory loss and more
5. Drug reduces fat by blocking blood vessels
6. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
7. Study finds depletion of alveolar macrophages linked to bacterial super-infections
8. Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth
9. High cholesterol fuels the growth and spread of breast cancer
10. Methylation signaling controls angiogenesis and cancer growth
11. Plant cell architecture: Growth toward a light source
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
(Date:3/2/2017)... , March 2, 2017 Summary ... understand Perrigo and its partnering interests and activities since 2010. ... Read ... Deals and Alliance since 2010 report provides an in-depth insight ... life sciences companies. On demand company reports are ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , ... software globally, announces significant enhancements to new and core ... 2016. New products include mobile and desktop Acuant FRM ... TM - a real time manual review of ... idScanĀ® technology provides the fastest and most accurate capture ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... ROCKVILLE, Md. , March 24, 2017 /PRNewswire/ ... Venture Fund (MBVF), today announced positive results of a ... standard drug therapy regimen in patients with multidrug-resistant pulmonary ... discovered by scientists at Sequella, Inc. ( USA ... A total of 140 patients were ...
(Date:3/24/2017)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), ... , today announced that its board of directors has amended its ... from March 27, 2017 to March 27, 2018. The amendment was not ... Biotech Ltd. ... Sinovac Biotech Ltd. is a China -based ...
(Date:3/24/2017)...   Sienna Biopharmaceuticals, Inc. , a privately held, ... Richard Peterson will join the company as ... who brings more than two decades of global financial ... retiring at the end of April but will continue ... Sienna from Novan, Inc., where he served as Chief ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
Breaking Biology Technology: